Bozitinib, also known as vebreltinib, is an orally bioavailable small-molecule inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor). It selectively binds to c-Met, disrupting its signal transduction pathways and inducing cell death in tumor cells that overexpress or have constitutively activated c-Met.
콘텐츠 범위: 이 페이지의 정보는 화학물질 식별 및 산업 공급·연구개발·제조 맥락을 대상으로 합니다. 치료 효능 주장, 의료 조언 또는 의약품 사용 지침에 해당하지 않습니다.
이 화합물을 구매하거나 공급하시겠습니까?
재고를 등록하거나 구매 요청을 게시하세요
CAS 1440964-89-5
Capmatinib hydrochloride
c-Met inhibitor active pharmaceutical ingredient
Ledipasvir acetone
active pharmaceutical ingredient
Ripretinib
kinase inhibitor active pharmaceutical ingredient
(1S,4R)-4-(2-Amino-6-(cyclopropylamino)-7-oxido-9H-purin-9-yl)-2-cyclopentene-1-methanol
Abacavir impurity reference standard
Landiolol hydrochloride
active pharmaceutical ingredient
6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine
QHXLXUIZUCJRKV-UHFFFAOYSA-N
CN1C=C2C=C(C(=CC2=N1)F)C(C3=NN=C4N3N=C(C=C4)C5=CN(N=C5)C6CC6)(F)F